Ad-hoc News

18.12.2017
MOLOGEN AG resolves first capital increase for the execution of the Share Subscription Facility concluded in October 2017

24.10.2017
MOLOGEN AG: US investor signs Share Subscription Facility

08.08.2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presents key results of the extension phase of the exploratory phase Ib/IIa TEACH trial, a cooperation with the Aarhus University Hospital in...

22.04.2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presents key results of the exploratory phase II IMPULSE study. The study was designed to evaluate efficacy and safety of the Company’s lead...

       

Share Subscription Facility with US investor GCF

Further Information

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com